Annovis: Imminent Alzheimer's Data Difficult to Handicap; Optimistic Overall
Aquestive Therapeutics (AQST): Underappreciated Late-Stage Assets Present Significant Long-Term Opportunity Despite Recent Gains
Annovis: Potentially Encouraging Patient Anecdotes and Weighing Phase 3 Parkinson’s Prospects
MAIA Biotechnology: Significantly Undervalued with Novel Mechanism and Impressive Early Data
